东北制药(000597) - 2023 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2023 was CNY 2,354,060,515.14, a slight increase of 0.02% compared to CNY 2,353,478,963.48 in the same period last year[5] - Net profit attributable to shareholders was CNY 70,050,130.06, representing a year-on-year increase of 2.51% from CNY 68,332,634.61[5] - Net profit for Q1 2023 was CNY 73,273,910.10, compared to CNY 72,594,482.98 in Q1 2022, showing an increase of 0.94%[16] - The total comprehensive income attributable to the parent company was CNY 69,857,492.43, compared to CNY 68,201,513.99 in the previous period, reflecting an increase of approximately 2.43%[17] - The total comprehensive income for minority shareholders was CNY 3,231,921.10, down from CNY 4,263,275.46 in the previous period, reflecting a decrease of approximately 24.23%[17] Cash Flow - The net cash flow from operating activities was CNY 114,351,104.00, down 56.42% from CNY 262,374,644.73 in the same period last year[5] - The net cash flow from operating activities was CNY 114,351,104.00, a decrease of 56.36% from CNY 262,374,644.73 in the previous period[20] - The company reported a significant increase of 454% in net cash flow from financing activities, amounting to CNY 327,000,000.00 due to increased bank loans[8] - The net cash flow from financing activities was CNY 327,001,976.11, compared to a negative cash flow of CNY -128,893,906.16 in the previous period, indicating a significant turnaround[20] - The total cash inflow from financing activities was CNY 2,600,055,207.14, compared to CNY 1,949,819,609.56 in the previous period, marking an increase of approximately 33.43%[20] - The cash outflow from operating activities totaled CNY 2,136,220,717.35, an increase of 18.56% from CNY 1,802,114,156.30 in the previous period[20] - The company recorded a net cash outflow from investing activities of CNY -28,879,694.93, an improvement from CNY -74,960,730.69 in the previous period[20] Assets and Liabilities - Total assets at the end of the reporting period were CNY 14,186,126,115.14, an increase of 2.72% from CNY 13,810,327,971.57 at the end of the previous year[5] - The total assets of the company reached CNY 14,186,126,115.14, up from CNY 13,810,327,971.57, indicating an increase of 2.72%[14] - The total liabilities increased to CNY 9,357,664,935.95 from CNY 9,097,072,806.91, which is an increase of 2.86%[14] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 81,145, with the top two shareholders holding a combined 53.84% of the shares[9] Expenses - The net profit after deducting non-recurring gains and losses decreased by 16.00% to CNY 44,510,180.83 from CNY 52,985,985.93 in the previous year[5] - Research and development expenses for the period were CNY 12,680,000.00, a decrease of 40% compared to the previous year[7] - R&D expenses decreased to CNY 12,681,127.16 from CNY 21,152,087.39, a reduction of 40.56%[16] - The company recognized equity incentive expenses of CNY 41,848,400.00 in Q1 2023, which, when excluded, resulted in a net profit of CNY 111,898,500.00, a year-on-year increase of 63.76%[5] Income and Revenue - The company received government subsidies amounting to CNY 23,038,409.48, contributing to a 44% increase in other income compared to the previous year[7] - The company reported sales revenue from goods and services of CNY 2,132,989,639.88, an increase of 8.68% compared to CNY 1,961,929,624.33 in the previous period[19] Inventory and Receivables - Accounts receivable rose to CNY 2,203,335,198.97 from CNY 1,975,198,452.07, marking an increase of 11.53%[13] - Inventory levels increased to CNY 1,370,524,466.26 from CNY 1,220,415,814.43, which is a rise of 12.31%[13] Borrowings - Short-term borrowings increased to CNY 2,130,000,000.00 from CNY 1,882,000,000.00, reflecting a growth of 13.14%[14] Earnings Per Share - The basic and diluted earnings per share were both CNY 0.049, down from CNY 0.051 in the previous period, reflecting a decrease of approximately 3.92%[17]